In the SOLAR-1 phase III clinical trial, addition of PI3K inhibitor, alpelisib, to fulvestrant was able to prolong progression-free survival (PFS) in patients with PIK3CA-mutated, hormone receptor positive, HER2-negative BC compared to fulvestrant alone (82). This evidence concerns the gene PIK3CA and breast cancer.